子宫内膜异位症/子宫腺肌病IVF患者——呼吁临床关注
本文为观点文章,指出子宫内膜异位症与子宫腺肌病(E/A)虽为不同疾病但共享相同的病理生理特征,均存在孕激素与雌激素信号通路紊乱导致的局部雌激素优势及受体水平孕激素抵抗。作者基于生理学及近期初步临床数据,提出通过全胚冷冻、降调节及增加黄体期孕激素补充等策略克服孕激素抵抗,并呼吁关注该亚组患者的研究。
要点
- E/A患者存在局部雌激素优势及孕激素受体抵抗,可能影响辅助生殖结局。
- 全胚冷冻后降调节及增加黄体期孕激素补充或可克服孕激素抵抗。
- 子宫腺肌病患者对促性腺激素释放激素激动剂降调节无反应时,芳香化酶抑制剂或为选择。
核心结论
- 子宫内膜异位症和子宫腺肌病是激素活性疾病,需通过控制局部高雌激素状态和孕激素抵抗进行治疗。
- 作者希望基于生理学和近期初步临床数据激发对E/A患者研究的讨论和兴趣。
研究设计与样本
- 本文为观点文章,基于生理学及近期初步临床数据论述。
主要发现
- 子宫内膜异位症和子宫腺肌病以孕激素和雌激素信号通路紊乱为特征,导致局部雌激素优势和受体水平孕激素抵抗。
- 近期科学证据提示,E/A患者的子宫内膜孕激素受体抵抗可通过全胚冷冻策略、冻融胚胎移植前降调节循环雌二醇浓度,并结合激素替代治疗冻融胚胎移植周期中增加外源性黄体期孕激素补充来克服。
- 对于子宫腺肌病患者,若促性腺激素释放激素激动剂降调节后循环雌二醇浓度未下降,小样本病例系列提示在激素替代治疗冻融胚胎移植前加用芳香化酶抑制剂21天为可行选择。
临床怎么用
- 作者提出,E/A患者可通过全胚冷冻后降调节及增加黄体期孕激素补充来克服孕激素抵抗。
- 作者提到,对促性腺激素释放激素激动剂降调节无反应的子宫腺肌病患者,加用芳香化酶抑制剂21天为可行选择,依据为小样本病例系列。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Endometriosis and adenomyosis are distinct clinical conditions that carry the same pathophysiological features. In recent years the clinical focus on assisted reproductive technology patients with either condition (E/A) has increased, in the recognition that this subgroup of patients might need special attention to obtain reproductive success. Endometriosis and adenomyosis are characterized by a disruption of progesterone and oestrogen signalling pathways, resulting in local oestrogen dominance and progesterone resistance at the receptor level. Recent scientific evidence suggests that the endometrial progesterone receptor resistance encountered in E/A patients can be overcome by a freeze-all policy, followed by down-regulating circulating oestradiol concentrations prior to frozen embryo transfer (FET), in combination with an increase in exogenous luteal phase progesterone supplementation in hormonal replacement therapy (HRT) FET cycles. Specifically, for adenomyosis patients who do not respond to gonadotrophin-releasing hormone agonist down-regulation in terms of a decrease in circulating oestradiol concentrations, a small case series has suggested that the addition of an aromatase inhibitor for 21 days prior to HRT-FET is a valid option. Endometriosis and adenomyosis are hormonally active diseases, which need to be treated by controlling local hyperoestrogenism and progesterone resistance. Based on physiology and recent preliminary clinical data, the authors of this opinion paper wish to stimulate discussion and spark interest in research in E/A patients.
引用
- Cozzolino M, Alsbjerg B, Pellicer A, et al. The adenomyosis/endometriosis IVF patient - call for clinical focus. Reprod Biomed Online. 2023. PMID: 38342076. doi:10.1016/j.rbmo.2023.103737
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。